Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
45.17
-2.28 (-4.81%)
At close: Apr 24, 2024, 4:00 PM
46.56
+1.39 (3.08%)
After-hours: Apr 24, 2024, 7:29 PM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 84.5, with a low estimate of 65 and a high estimate of 94. The average target predicts an increase of 87.07% from the current stock price of 45.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Buy | 6 | 5 | 5 | 5 | 6 | 7 |
| Hold | 1 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $87 | Strong Buy | Reiterates | $87 | +92.61% | Apr 23, 2024 |
| Scotiabank | Scotiabank | Hold → Buy Upgrades $65 | Hold → Buy | Upgrades | $65 | +43.90% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $87 | Strong Buy | Reiterates | $87 | +92.61% | Apr 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $82 | Buy | Initiates | $82 | +81.54% | Apr 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $87 | Strong Buy | Reiterates | $87 | +92.61% | Apr 1, 2024 |
Financial Forecast
Revenue This Year
609.28M
from 285.14M
Increased by 113.68%
Revenue Next Year
1.11B
from 609.28M
Increased by 82.35%
EPS This Year
-1.51
from -2.94
EPS Next Year
-0.59
from -1.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 737.0M | 1.6B | 2.4B | 3.0B | 3.7B |
| Avg | 609.3M | 1.1B | 1.7B | 2.4B | 3.0B |
| Low | 441.0M | 824.6M | 1.1B | 1.7B | 2.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 158.5% | 162.9% | 120.3% | 80.0% | 51.7% |
| Avg | 113.7% | 82.3% | 52.1% | 43.9% | 21.3% |
| Low | 54.7% | 35.3% | -2.6% | 1.1% | -17.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.53 | 0.44 | 2.45 | 3.98 | 4.89 |
| Avg | -1.51 | -0.59 | 0.72 | 2.53 | 3.41 |
| Low | -2.68 | -1.68 | 0.04 | 1.14 | 1.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 453.1% | 93.7% |
| Avg | - | - | - | 251.1% | 35.0% |
| Low | - | - | - | 58.0% | -30.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.